Improving Diagnosis of Bladder Cancer

改善膀胱癌的诊断

• 批准号: 8230252
• 负责人: BOGDAN A CZERNIAK
• 金额: $ 20.32万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8230252
• 关键词: Address; Affect; Bedside Testings; Biological Markers; Biopsy; Bladder; Bladder Neoplasm; Cancer Detection; Carcinoma in Situ; Cell Cycle; Cells; Cessation of life; Chromosome Mapping; Chronology; Clinical; Complement; Coupled; Cystectomy; Cystoscopy; Cytology; DNA; Data; Detection; Development; Diagnosis; Diagnostic tests; Disease; Distant Metastasis; Early Diagnosis; Early treatment; Event; Frequencies; Gene Expression Profiling; Gene Targeting; Genes; Genomics; Genotype; Goals; Grant; Growth; Hematuria; Histologic; Human; In Vitro; Instruction; Licensing; Malignant Neoplasms; Malignant neoplasm of urinary bladder; Maps; Modeling; Monitor; Neoplasm Metastasis; Organ; Papillary; Pathway interactions; Patients; Performance; Phase; Protocols documentation; Resolution; Role; Sampling; Sensitivity and Specificity; Survival Rate; Techniques; Testing; United States; Urine; Urogenital Cancer; Validation; angiogenesis; aurora-A kinase; base; cancer cell; cancer invasiveness; clinically significant; design; genome-wide; high risk; human STK6 protein; improved; in vivo; men; minimally invasive; novel; novel diagnostics; overexpression; tumor progression

The long-term objective of this project is to improve the detection of one of the common human cancers arising in the bladder by non-invasive voided urine-based tests. Bladder cancer is the 4"^ most frequent in men and 5"" most common overall with approximately 70,500 new cases and 14,600 deaths from the disease in 2009 in the United States. It is estimated that nearly 300,000 patients are regularly monitored in the United States through a vanety of non-invasive (urine) and minimally invasive (bladder barbotage, cystoscopy, and biopsy) techniques. Therefore, the development of novel biomarkers that can detect bladder tumors by a non-invasive approach is of major clinical significance. In this grant, we propose to complement the existing Multi-Institutional Aurora kinase A FISH Test Biomarker Validation Trial by novel FISH markers and explore the role of Aurora kinase A in bladder cancer progression. We will compare the specificity and sensitivity of aurora A FISH test complemented by a panel of novel FISH markers with other known noninvasive bladder cancer detection tests for voided urine sediments such as urine cytology and commercially available multi-chromosomal FISH kit known as UroVysion, and NMP22 point-of-care test. A panel of novel FISH markers will be developed by whole-organ histologic and genetic mapping (WOHGM) strategy combined with high resolution (IM) lllumina SNP-based genotyping, which provides unique information on the chronology of genomic alterations that parallel the development of bladder cancer from early field effects to invasive disease. Our strong preliminary data indicate that this approach offers a unique opportunity to design novel biomarkers that may address the specific phases of bladder cancer development along these superficial papillary and high grade nonpapillary Invasive pathways. Moreover, we propose to investigate the role of aurora kinase A and its regular pathway in bladder cancer progression to invasive disease and distant metastasis. The specific aims of this project are as follows: Specific Aim 1: Develop a panel of novel FISH markers for bladder cancer. Specific Aim 2: Validate a novel set of FISH biomarkers for bladder cancer. Specific Aim 3: Investigate the role of Aurora kinase A in bladder cancer growth, angiogenesis, invasion and metastasis.

该项目的长期目标是改善对人类常见癌症之一的检测 通过非侵入性的基于排尿的测试在膀胱中产生。膀胱癌是世界上最常见的癌症。 男性和5”最常见的总体约70，500例新病例和14，600例死亡的疾病 2009年在美国。据估计，近300，000名患者定期监测， 美国通过各种无创（尿液）和微创（膀胱barbotage， 膀胱镜检查和活组织检查）技术。因此，开发新的生物标志物，可以检测 膀胱肿瘤的非侵入性方法具有重要的临床意义。在这项拨款中，我们建议 补充现有的多机构极光激酶A FISH测试生物标志物验证试验， FISH标记物，并探讨极光激酶A在膀胱癌进展中的作用。我们将比较 Aurora A FISH检测的特异性和灵敏度，由一组新的FISH标记物与其他 已知的用于排出的尿沉淀物的非侵入性膀胱癌检测测试， 市售多染色体FISH试剂盒（称为UroVysion）和NMP 22即时检测。一 一组新的FISH标记物将通过全器官组织学和遗传作图（WOHGM）开发 结合高分辨率（IM）Illumina基于SNP的基因分型策略， 关于与膀胱癌的发展平行的基因组改变的时间顺序的信息， 侵袭性疾病的早期现场影响。我们强大的初步数据表明，这种方法提供了一个独特的 有机会设计新的生物标志物，可以解决膀胱癌发展的特定阶段 沿着这些浅表乳头状和高度非乳头状侵入性通路。此外，我们建议 研究极光激酶A及其调控通路在膀胱癌向浸润性转移中的作用。 疾病和远处转移。该项目的具体目标如下：具体目标1： 一组新的膀胱癌FISH标记物。具体目标2：建立一套新的FISH生物标志物 治疗膀胱癌具体目标3：研究极光激酶A在膀胱癌生长中的作用， 血管生成、侵袭和转移。